In this issue

Human Vaccines & Immunotherapeutics
Volume 9, Issue 5
May 2013
View current issue

Most Popular Downloads

01 Nov 12
01 Nov 12
01 Jan 12
01 Apr 13
01 Aug 12
News
Eva M. Riedmann

Landes Highlights

Articles of interest recently published in our other journals

Editor-in-Chief

Ronald Ellis PhD
Senior Vice President R&D and Chief Technology Officer
NasVax Ltd., Ness Ziona, Israel

Email the Managing Editor, Betsy Granger.
Email the Acquisitions Editor, Eva M. Riedmann.
Print ISSN: 2164-5515
Online ISSN: 2164-554X
IF: 3.577
Abstracted/Indexed In:
Medline/PubMed, PubMed Central, Science Citation Index Expanded (available as the ISI Web of Science, ISI Alerting Services, Biosis Previews and Biological Abstracts).

Open Access in

Human Vaccines & Immunotherapeutics

Human Vaccines & Immunotherapeutics offers a highly competitive open access fee for authors who wish for free access to and distribution of published articles. Authors retain copyright of their work by utilizing a Creative Commons attribution license. Open Access papers will be submitted to PubMed Central immediately upon final publication of each issue.

Open Access Fees

Research Papers and Reports, OA fee is $750.00 USD

Reviews, Brief Reports and Short Communications, OA fee is $500.00 USD

All other types of papers, OA fee is $250.00


Find us on Facebook

Submit your paper to Human Vaccines & Immunotherapeutics

Human Vaccines & Immunotherapeutics (HV&I) utilizes an online submission and tracking system designed to provide efficient service to authors. Through the online system, author files are automatically converted to PDFs, submissions are acknowledged by email, and authors can track their manuscript through the stages of the peer review process.

Click here to submit your manuscript to HV&I.

HV&I is indexed in Medline/PubMed and in the Science Citation Index Expanded.


Advertisements